期刊文献+

卵巢癌患者血清人附睾分泌蛋白4水平及其临床意义 被引量:4

下载PDF
导出
摘要 目的:探讨卵巢癌患者血清人附睾分泌蛋白4(HE4)水平及其临床意义。方法:采用电化学发光法(ECL)对50例卵巢癌患者及60例正常对照组进行血清中HE4的含量测定,分析卵巢癌组临床病理特征与血清HE4水平的关系。结果:卵巢癌组血清HE4显著高于妇科良性疾病组和正常对照组(P<0.01)。临床FIGO分期Ⅲ、Ⅳ期患者血清HE4浓度也明显高于Ⅰ、Ⅱ期患者(P<0.01),有淋巴结转移的患者血清HE4水平明显高于无淋巴结转移的患者,治疗有效组HE4水平明显低于治疗前,差异有显著性意义(P<0.01)。结论:血清HE4水平可作为卵巢癌诊断、判断恶性程度及是否转移、观察疗效的有效指标。
作者 张浩 张绍武
出处 《陕西医学杂志》 CAS 2012年第6期729-730,共2页 Shaanxi Medical Journal
  • 相关文献

参考文献7

二级参考文献36

  • 1Ozols RF, Bookman MA, Connolly DC, et al, Focus on epithelial ovarian cancer. Cancer Cell, 2004,5 : 19-24.
  • 2Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002,359: 572-577.
  • 3Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HFA (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 2003, 63:3695-3700.
  • 4Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol, 2009,112:40-46.
  • 5Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991, 45:350-357.
  • 6Drapkin R,Von Horsten HH, Lin YF, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 2005,65:2162-2169.
  • 7Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol, 2008,108:402-408.
  • 8Bast RC Jr, Klug TL, St John E, et al. A radio ty using a monoclonal antibody to monitor the course of epithelial ovarian cancer[ J ]. N Engl J Med, 1983,309:883- 887.
  • 9Jacobs I, Bast RC Jr. The CA 125 tumor-associated antigen : a review of the literature [ J ]. Hum Reprod, 1989,4 : 1- 12.
  • 10Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA125 ,ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer [J]. Br J Obstet Gynaecol, 1990,97:922-929.

共引文献67

同被引文献30

  • 1贾晓辉,由甲申.卡铂腹腔灌注联合紫杉醇全身化疗治疗晚期卵巢癌[J].中国实用医药,2007,2(32):75-76. 被引量:5
  • 2戴芙蓉,张怡,陈呈祥.老年妇女子宫内膜癌预后因素分析[J].医学临床研究,2005,22(8):1041-1044. 被引量:3
  • 3宣小山.综合性治疗晚期卵巢癌八例30年随访报告[J].中国基层医药,2012,19(增刊):52.
  • 4Fujiwara K, Armstrong D, Morgan M, et al. Principles and practice of intraperitoneal chemtherapy for ovarian cancer[ J 1. Int J Gyne- col Cancer,2007,17 ( 1 ) : 1-20.
  • 5Hess LM, Alberts DS. The role of intraperitoneal therapy in ad- vanced ovarian cancer[ J]. Oncology,2007,21 (2) :227-232.
  • 6Vander Zee 'J. Heating the patient : a promising approach [ J ]. Ann Oncoi ,2009,13 ( 8 ) : 1173-1184.
  • 7Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecu- lar basis of hyperthermia[ J ]. Crit Rev Oncol Hematol,2008,43 (1) :33-56.
  • 8Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [J]. CA Cancer Clin ,2005,55(1):10-30.
  • 9Sedlrkova I, Vrvrov J, Tosner J, et al. Lysophosphatidic acid in ovarian caneer patients [ J ]. Ceska Gyriekol, 2006,71 ( 4 ) : 312- 317.
  • 10Barbieri RL. In women who have a pelvic mass Have youtried this new ovarian Ca biomarker[J].OBG Management,2010,22 (4) : 8-12.

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部